Jorey Chernett, identified as holding approximately 10% of Oncology Institute, Inc. (NASDAQ:TOI), increased his direct ownership in the company by acquiring 20,000 shares of common stock on April 9, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were bought at $3.10 each, for a total purchase value of $62,000. After the transaction, Chernett's direct ownership stands at 10,499,358 shares.
The insider purchase takes place while TOI shares have produced a 72% return over the trailing 12 months. Market analysis from InvestingPro cited in the filing notes that the stock is trading above its Fair Value, indicating that InvestingPro considers TOI to be overvalued at current levels. Despite that assessment, sell-side analysts maintain price targets in the $5 to $8 range. The company has its next quarterly earnings report on the calendar for May 13.
Investors following TOI have additional information available from InvestingPro, which the filing references as offering further tips and a broader analytical package on the company.
Recent company disclosures add context to the insider buy. The Oncology Institute reported fourth-quarter results for 2025 that outperformed analyst expectations. The firm recorded diluted earnings per share of -$0.06, beating the consensus forecast of -$0.09. Revenue for the quarter was $141.96 million, above the $139.79 million anticipated by analysts. The quarterly figures were characterized in company communications as a positive surprise relative to estimates.
Separately, The Oncology Institute announced the appointment of Minh Merchant as Chief Legal Officer. Merchant will be responsible for overseeing the company’s legal, regulatory, compliance, and privacy functions and is described as having more than 20 years of experience in the healthcare sector. The company framed these moves as part of its ongoing organizational developments.
No additional details about the Form 4 filing, such as whether the purchase was executed under a prearranged plan, were included in the disclosure. The information available is limited to the date of purchase, the number of shares, the per-share price, the total transaction value, and the updated shareholdings reported on the SEC filing.